Biovaxys Technology Corp (BVAXF)

$0.16 +0.04 (29.37%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 418,482
Avg Vol 125,982
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 57%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell...

Industry: Biotechnology
Sector: Healthcare
Phone: 740-358-0555
Address:
146 Thirtieth Street, Suite 100, Etobicoke, Canada
FLArnot
FLArnot May. 22 at 7:24 PM
$BVAXF If they sign an LOI or DA for a license deal as this comes out of halt in Canada, these prices will never be seen again. All comparable license deals in the market have been 100 million plus. And it is unfair to call it comparable as DPX is superior in every way, including low to no refrigeration needed, oil based, and now shown to manage mRNA, cancer, vaccine, allergy applications. It is a TRUE PLATFORM, not a one up.
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 22 at 5:57 PM
thin float. CSE halted. naked short positions built across OTC and Frankfurt. Ebola narrative shifted. May 31 filing is the trigger. $BVAXF $MRK $AEMD $EBS $REGN
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 22 at 5:57 PM
BioVaxys acquired IMV's entire IP portfolio in 2024. that includes the DPX Ebola NIH data. they own the foundation to build on. $BVAXF $MRK $AEMD $EBS $REGN
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 22 at 5:55 PM
two dose regimen. day 0 and day 56. challenge on day 70. $BVAXF BioVaxys DPX Ebola vaccine gave full protection within that window. $MRK $AEMD $EBS $REGN
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 22 at 5:47 PM
NIAID ran the study under their preclinical services program. not BioVaxys running their own tests. independent NIH infrastructure validating DPX Ebola results. $BVAXF $MRK $AEMD $EBS $REGN
0 · Reply
FLArnot
FLArnot May. 22 at 5:33 PM
$BVAXF STRONG Ebola news with high CEPI interest, and a market cap UNDER 5 million! This ground floor will not last long. Get in before someone else gets the cheap shares.
0 · Reply
Davidendz
Davidendz May. 22 at 5:28 PM
Ebola news + $BVAXF dropping their strong DPX monkey study (full protection!) = potential volume spike and quick re-rating for the stock right now. Smart timing that puts $BVAXF back on the radar alongside $MRK $REGN $EBS $AEMD.
0 · Reply
Davidendz
Davidendz May. 22 at 5:26 PM
Expect a surge in attention, trading volume, and share price momentum as the market wakes up to this hidden platform gem $BVAXF $MRK $REGN $EBS $AEMD.
0 · Reply
Davidendz
Davidendz May. 22 at 5:26 PM
This is the spark $BVAXF needed! With the Bundibugyo Ebola PHEIC exploding in DRC and no vaccine ready, their NIH DPX-Ebola data showing 100% survival is pure rocket fuel
0 · Reply
Davidendz
Davidendz May. 22 at 5:24 PM
$BVAXF revisiting Ebola vaccine study: monkeys received DPX formulation, challenged day 70 with wild-type lethal virus. 100 percent survival, no symptoms. Controls dead in 7 days. DRC emergency now $MRK $AEMD $EBS $REGN $BVAXF
0 · Reply
Latest News on BVAXF
No data available.
FLArnot
FLArnot May. 22 at 7:24 PM
$BVAXF If they sign an LOI or DA for a license deal as this comes out of halt in Canada, these prices will never be seen again. All comparable license deals in the market have been 100 million plus. And it is unfair to call it comparable as DPX is superior in every way, including low to no refrigeration needed, oil based, and now shown to manage mRNA, cancer, vaccine, allergy applications. It is a TRUE PLATFORM, not a one up.
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 22 at 5:57 PM
thin float. CSE halted. naked short positions built across OTC and Frankfurt. Ebola narrative shifted. May 31 filing is the trigger. $BVAXF $MRK $AEMD $EBS $REGN
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 22 at 5:57 PM
BioVaxys acquired IMV's entire IP portfolio in 2024. that includes the DPX Ebola NIH data. they own the foundation to build on. $BVAXF $MRK $AEMD $EBS $REGN
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 22 at 5:55 PM
two dose regimen. day 0 and day 56. challenge on day 70. $BVAXF BioVaxys DPX Ebola vaccine gave full protection within that window. $MRK $AEMD $EBS $REGN
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 22 at 5:47 PM
NIAID ran the study under their preclinical services program. not BioVaxys running their own tests. independent NIH infrastructure validating DPX Ebola results. $BVAXF $MRK $AEMD $EBS $REGN
0 · Reply
FLArnot
FLArnot May. 22 at 5:33 PM
$BVAXF STRONG Ebola news with high CEPI interest, and a market cap UNDER 5 million! This ground floor will not last long. Get in before someone else gets the cheap shares.
0 · Reply
Davidendz
Davidendz May. 22 at 5:28 PM
Ebola news + $BVAXF dropping their strong DPX monkey study (full protection!) = potential volume spike and quick re-rating for the stock right now. Smart timing that puts $BVAXF back on the radar alongside $MRK $REGN $EBS $AEMD.
0 · Reply
Davidendz
Davidendz May. 22 at 5:26 PM
Expect a surge in attention, trading volume, and share price momentum as the market wakes up to this hidden platform gem $BVAXF $MRK $REGN $EBS $AEMD.
0 · Reply
Davidendz
Davidendz May. 22 at 5:26 PM
This is the spark $BVAXF needed! With the Bundibugyo Ebola PHEIC exploding in DRC and no vaccine ready, their NIH DPX-Ebola data showing 100% survival is pure rocket fuel
0 · Reply
Davidendz
Davidendz May. 22 at 5:24 PM
$BVAXF revisiting Ebola vaccine study: monkeys received DPX formulation, challenged day 70 with wild-type lethal virus. 100 percent survival, no symptoms. Controls dead in 7 days. DRC emergency now $MRK $AEMD $EBS $REGN $BVAXF
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 22 at 4:19 PM
$BVAXF
0 · Reply
NewMexicats
NewMexicats May. 22 at 4:16 PM
$BVAXF Original IMV ebola study https://www.bioworld.com/articles/394458-immunovaccine-reports-success-protecting-animals-from-ebola?utm_source=chatgpt.com
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 22 at 4:13 PM
wild type Zaire strain. the deadliest Ebola species. $BVAXF BioVaxys DPX vaccine protected all four monkeys against it. controls all died. $MRK $AEMD $EBS $REGN
0 · Reply
wheresdannynow
wheresdannynow May. 22 at 4:06 PM
Breaking Ebola concerns in DRC. $BVAXF has historical DPX data showing full protection against lethal Ebola in primates after just 2 doses. Study partners NIH/NIAID $MRK $AEMD $EBS $REGN $BVAXF
0 · Reply
wheresdannynow
wheresdannynow May. 22 at 4:04 PM
$BVAXF looking into prior DPX-Ebola vaccine that gave 100 percent survival in lethal monkey challenge. Timing lines up with current DRC public health emergency. Eyes on $MRK $AEMD $EBS $REGN $BVAXF
0 · Reply
wheresdannynow
wheresdannynow May. 22 at 4:03 PM
All vaccinated monkeys alive and healthy more than 2 weeks post lethal dose. Controls died fast $MRK $AEMD $EBS $REGN $BVAXF
0 · Reply
wheresdannynow
wheresdannynow May. 22 at 4:03 PM
With Ebola news dominating, $BVAXF is revisiting their successful NIH/NIAID DPX-Ebola challenge study
0 · Reply
wheresdannynow
wheresdannynow May. 22 at 4:02 PM
Study showed complete protection in primates versus wild-type lethal Ebola. Strong data $MRK $AEMD $EBS $REGN $BVAXF
0 · Reply
wheresdannynow
wheresdannynow May. 22 at 4:02 PM
$BVAXF DPX-Ebola program back in focus after WHO declares DRC outbreak emergency.
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 22 at 3:28 PM
DepoVax was the original name for DPX. IMV ran the Ebola study. $BVAXF BioVaxys acquired IMV and all its IP including this Ebola data. $MRK $AEMD $EBS $REGN
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 22 at 3:24 PM
$BVAXF $MRK $AEMD $EBS $REGN
0 · Reply
Ventureville
Ventureville May. 22 at 3:22 PM
Ebola experts warning of scale and spread. $BVAXF revisiting DPX-Ebola monkey study: 2 doses, day 70 lethal challenge, 100 percent survival, zero disease. Controls gone in a week. Potential response candidate https://www.dw.com/en/ebola-experts-warn-of-scale-and-spread-of-deadly-virus/a-77248583
0 · Reply